ATLASJPMorgan International Value ETF (JIVE): outlook, holdings and fees
JPMorgan International Value ETF (JIVE) is an exchange-traded fund and is managed by JPMorgan. The expense ratio is 0.56% and the yield is 1.90%. The ten largest holdings are 17% of the fund.
Fund data as of Oct 14, 2026 · Price Nov 2, 2026
ATLAS view on JIVE
| Last price | $94.46 (+0.7%) |
|---|---|
| ATLAS chance of a higher price in 1 month | 57% |
| Likely 1-month range (50%) | $93.05 – $96.91 |
| Normal 1-day range (±1σ) | ±0.7% |
| Distribution yield | 1.90% |
ATLAS probabilities use the same calibrated model as every stock page. A fair value is shown for companies, not funds; the holdings below link to the fair value of each company.
JIVE fund facts
| Issuer | JPMorgan |
|---|---|
| Theme | International developed |
| Assets under management | $4.2B |
| Expense ratio | 0.56% |
| Number of holdings | 49 |
| Portfolio turnover | 4% |
| Inception | Sep 13, 2023 |
| Exchange | NASDAQ |
The fund invests primarily in equity securities and equity-related instruments of foreign companies, including foreign subsidiaries of U.S. companies. The fund may invest in issuers located in both developed foreign and emerging market countries. Developed foreign countries include Australia, Canada, Israel, Japan, New Zealand, Singapore, the United Kingdom, most of the countries of Western Europe and Hong Kong; emerging market countries include most of the other countries in the world.
JIVE top holdings
| Holding | Sector | Weight |
|---|---|---|
| Samsung Electronics Co Ltd SSNLF | Technology | 3.76% |
| Taiwan Semiconductor Manufacturing Co. Ltd. 2330 | Technology | 2.79% |
| Shell plc SHEL | Energy | 1.69% |
| Nestle S.A. NESN | Consumer Defensive | 1.45% |
| Roche Holding AG ROP | Healthcare | 1.38% |
| Toronto Dominion Bank 8640 | – | 1.34% |
| HSBC Holdings PLC HSBA | Financial Services | 1.24% |
| Novartis AG NOVN | Healthcare | 1.14% |
| Allianz SE VNA O.N. ALV | Financial Services | 0.98% |
| Royal Bank of Canada RY | Financial Services | 1.06% |
Holdings with an ATLAS page link to their probability range, fair value and earnings calendar.
JIVE sector breakdown
| Sector | Weight |
|---|---|
| Financial Services | 39.1% |
| Energy | 11.1% |
| Industrials | 9.9% |
| Technology | 9.8% |
| Consumer Cyclicals | 6.9% |
| Healthcare | 5.8% |
| Consumer Defensive | 5.1% |
| Basic Materials | 4.5% |
| Communication Services | 4.1% |
| Real Estate | 1.9% |
| Utilities | 1.8% |
By region: Europe Developed 36.1%, Asia Developed 18.6%, Japan 11.2%, United Kingdom 10.4%, Asia Emerging 10.3%.
JIVE returns and risk
| Year to date | +18.4% |
|---|---|
| 1 year | +30.0% |
| 3 years (annualised) | +28.5% |
| Volatility (3 years) | 11.3% |
| Sharpe ratio (3 years) | 1.75 |
Past returns do not guarantee future results.
JIVE: frequently asked questions
What does JIVE invest in?
JPMorgan International Value ETF invests in a portfolio of securities. Its largest holdings are Samsung Electronics Co Ltd (3.8%), Taiwan Semiconductor Manufacturing Co. Ltd. (2.8%), Shell plc (1.7%), Nestle S.A. (1.5%), Roche Holding AG (1.4%).
What is the JIVE expense ratio?
0.56% a year: about $56.00 for every $10,000 invested.
What is the JIVE dividend yield?
1.90%. ATLAS does not hold the exact distribution dates for ETFs.
Will JIVE go up?
Nobody can know. The ATLAS model puts the chance of a higher price in one month at 57%, with a likely range (50%) of $93.05 to $96.91 from $94.46 today. It is a probability, not a prediction.
How has JIVE performed?
Year to date +18.4%, one year +30.0%, three years +28.5% a year. Past returns do not guarantee future results.
Similar ETFs: International developed
- Vanguard FTSE Developed Markets ETF (VEA)
- iShares Core MSCI EAFE ETF (IEFA)
- Vanguard Total International Stock ETF (VXUS)
- iShares MSCI EAFE ETF (EFA)
- Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU)
- Schwab International Equity ETF (SCHF)
- iShares Core MSCI Total International Stock ETF (IXUS)
- State Street SPDR Portfolio Developed World ex-US ETF (SPDW)
Educational information, not investment advice. Disclaimer